TLDR
- PSTV stock jumps as CNSide expands its national coverage with Humana.
- PSTV gains momentum with the new Humana partnership for CNSide diagnostic.
- CNSide Diagnostics boosts PSTV stock with national Humana agreement.
- Plus Therapeutics stock rises after CNSide expands its reach to millions via Humana.
- PSTV’s CNSide platform gains national coverage, boosting investor confidence.
Plus Therapeutics (PSTV) saw its stock price rise by 4.57% to $0.5125 earlier today, reflecting investor optimism. After reaching the peak, the stock faced a decline, exhibiting notable volatility. The price fluctuation highlights market uncertainty despite a significant business development for the company.
Plus Therapeutics, Inc., PSTV
CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics, signed a major national agreement with Humana, Inc. The deal, effective October 29, 2025, grants Humana coverage to approximately 16 million people across the U.S. With this agreement, the CNSide Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) laboratory-developed test (LDT) now has total policy coverage for 67 million people.
Major Coverage Agreement with Humana
The national agreement between Plus Therapeutics and Humana provides broad coverage for the CNSide CSF Tumor Cell Enumeration (TCE) test. The test plays a vital role in diagnosing leptomeningeal metastases, a complex condition in cancer patients. With Humana’s coverage, millions more people will have access to this innovative diagnostic tool.
The CNSide CSF Assay Platform has demonstrated its clinical utility in improving patient outcomes. Through the analysis of cerebrospinal fluid, it helps in the diagnosis, monitoring, and treatment guidance of patients. The platform has proven effective, with sensitivity reaching 92% and specificity at 95%, according to recent peer-reviewed studies.
CNSide Diagnostics has already completed over 11,000 tests since 2020, gaining traction across more than 120 U.S. cancer centers. The company claims that the CNSide® test has influenced treatment decisions in 90% of cases. This growing real-world evidence underscores the test’s clinical relevance and importance in cancer care.
Stock Performance Reflects Market Reaction
The agreement with Humana provides significant momentum for Plus Therapeutics and its subsidiary, CNSide Diagnostics. Plus Therapeutics saw an immediate 4.57% increase in stock value. Despite the subsequent decline from its peak, this surge reflects investor confidence in the long-term potential of the company’s diagnostic offerings.
The volatility in the stock price today shows that market reactions can be unpredictable. The company’s performance will likely continue to be influenced by factors such as clinical results, regulatory decisions, and the broader healthcare market. The strategic move to expand CNSide test coverage strengthens Plus Therapeutics’ position in the diagnostic and oncology space.
As Plus Therapeutics continues to expand its reach through partnerships like the one with Humana, the company is poised for future growth. The expanding coverage of CNSide tests aligns with the growing demand for innovative cancer diagnostics. Moving forward, Plus Therapeutics will likely remain in the spotlight as it capitalizes on the market potential of its cutting-edge platform.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
